Introduction
Hepatocellular carcinoma (HCC) is the second most common cause of cancer death (1). It arises on a background of chronic liver diseases, such as viral hepatitis, alcoholic liver disease (ALD), and, increasingly, non-alcoholic liver disease (NAFLD; ref. 2) . Cirrhosis and advanced HCC stage at presentation in the majority of patients severely restricts both surgical and nonsurgical therapeutic options. Curative treatments are limited to patients with early cancers who are fit enough for resection, liver transplantation, or radiofrequency ablation (3) . HCC resistance to conventional palliative cytotoxic agents is compounded by increased toxicity, attributed to hepatic metabolism and their reduced clearance in patients with impaired liver function. Sorafenib represents a major advance in the medical management of these patients (4) , but the survival benefit is modest (4) . The need to identify key drivers of hepatocarcinogenesis and chemoradioresistance, as well as biomarkers to target therapy effectively, is of paramount importance.
The most widely used palliative treatment for fit patients with intermediate stage HCC [Barcelona Clinic for Liver Cancer (BCLC) stage "B"] is transarterial chemoembolization (TACE). Its overall efficacy, however, is questionable and patient selection is key (3) . Tumor-directed radiotherapy is promising (5, 6) but as yet has no proven benefit. Both radiotherapy and the cytotoxic drugs used in TACE cause DNA damage, to which the cell mounts a DNA damage response (DDR). DNA double-strand breaks (DSB) are the most cytotoxic and are repaired by two major pathways, with nonhomologous end joining (NHEJ) being the most active in both replicating and nonreplicating cells alike.
Crucial to NHEJ is DNA-dependent protein kinase (DNA-PK), a heterodimeric enzyme consisting of Ku70, Ku80, and the catalytic subunit DNA-PKcs, encoded by protein kinase DNA-activated catalytic polypeptide (PRKDC). DNA-PK phosphorylates a variety of cellular proteins, including autophosphorylation of DNAPKcs at serine2056 (7) . Upregulated DNA repair activity is often evident in established cancers (8) , potentially contributing to therapeutic resistance. DNA-PK inhibitors in preclinical development have been shown to sensitize human cancer cells and tumor xenografts to ionizing radiation (IR) and topoisomerase II poisons (9) . NU7441 is a potent and selective DNA-PK inhibitor (in vitro IC 50 ¼ 14 nmol/L), demonstrating excellent sensitization in breast and colon cancer cell lines (10) . The association between PRKDC expression and DNA-PK levels or activity in HCC is scant, but some evidence for an increase is documented (11, 12) . The aim of the current study was to determine the prognostic significance of DNA-PK expression and activity in human HCC and explore the therapeutic potential of DNA-PK inhibition in vitro and in vivo.
Materials and Methods

Patient cohorts
Cohort 1 included tissues from consented consecutive patients undergoing resection or liver transplantation at three university hospitals in the United States (Mount Sinai Hospital, New York, NY) and Europe (Hospital Clínic, Barcelona, Spain, and National Cancer Institute, Milan, Italy) as described previously (13, 14) . Patients with extrahepatic spread were excluded. Specific analyses are as described in Fig. 1 . Cohort 2 was a case series of 45 patients (Table 1) undergoing pretreatment diagnostic biopsy, either because there was no history/evidence of associated cirrhosis or because of radiological diagnostic doubt, from a total of 632 patients managed in Newcastle between 2000 and 2010 (2) . Those who did not consent to the use of their surplus tissues after diagnostic purposes were excluded. Patients were followed until June 30, 2013.
Immunohistochemistry
Using formalin-fixed paraffin-embedded tissues, HCC grading was by two pathologists (15) . A detailed immunohistochemistry (IHC) protocol is described in Supplementary Methods. Briefly, antigen retrieval was with an Antigen Access Unit (A. Menarini Diagnostics). Antibodies: anti-DNA-PKcs (rabbit polyclonal, H-163; 1:500; Santa Cruz Biotechnology), anti-phosphorylated Ser2056 DNA-PKcs (rabbit polyclonal, ab20407; 1:500; Abcam), anti-ATM (rabbit polyclonal, MAT3-4G10/8; 1:800; Sigma), antiphosphorylated Ser1981 ATM (rabbit polyclonal, AF1655; 1:300; R&D Systems). Sections were analyzed using Aperio Image analysis. Hepatocyte nuclei were identified using a modified nuclear algorithm and staining quantified in pixels after background subtraction. The selection of normal versus tumor areas was by a pathologist, whereas the application of the quantification algorithm was by supervised researchers. Both pathologists and researchers were blinded until the study endpoint.
Cell lines and in vitro assays
HCC cell lines SNU-182, SNU-475, HepG2, Hep3B, Huh7 (ATCC), and PLC/PRF/5 (ECACC) were maintained as per suppliers guidelines. All cell lines were authenticated (LGC Standards) and free of Mycoplasma contamination (MycoAlert Assay; Cambrex Bio Science). Mean change in gene expression (AESEM), using Human DNA Repair PCR Profiler Arrays (SA Biosciences; Qiagen), was expressed as DDC t relative to HPRT1. Western blotting was as described previously (16) . Image acquisition/ densitometry was performed using a G-box chemiluminescent image analyzer (Syngene). gH2AX and RAD51 foci detection was as previously described (17) . Cell survival was assessed by colony formation and automated counting, normalized to untreated control (AESEM; ref. 16 ). ShRNA-mediated knockdown of DNA-PKcs and subsequent analysis of double-strand break repair (DSBR) activity using the traffic light reporter system (18, 19) are detailed in Supplementary Methods.
Xenograft model
Female nude mice (CD1 nu/nu; Charles River) were maintained as previously described (16) . Huh7 cells (1 Â 10 7 in 50 mL culture medium) were implanted subcutaneously. NU7441 (10 mg/kg i.p.) and/or doxorubicin (2 mg/kg i.p.) were administered to tumor-bearing mice daily for 5 days.
Statistical analysis
Data were analyzed using SPSS statistics (version 19.0). A twoway ANOVA was used for clonogenic and immunofluorescence assays, paired t tests were used to compare tumor versus normal tissue, and a log-rank test (Mantel-Cox) and Cox proportional hazards regression were used for survival analyses.
Chemicals
Chemicals were from Sigma unless stated otherwise. Antibodies: anti-RAD51 antibody (rabbit polyclonal, sc-8349; Santa Cruz Biotechnology); Ku70 (monoclonal, ab3114), Ku80 (monoclonal, ab3107), from Abcam; actin (mouse, monoclonal, Ab-1; Calbiochem, Merck Biosciences); anti-gH2AX (monoclonal, 05-636; Millipore).
Results
Amplification of PRKDC in HCC in association with increased mRNA levels Expression of genes involved in the DDR was evaluated in a cohort of 132 samples (13, 14) of normal, chronically diseased,
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Increased HCC nuclear DNA-PKcs and treatment resistance
Nuclear DNA-PKcs protein levels assessed by IHC in paired tumor and nontumor liver from an independent cohort of 45 patients (Table 1) were scored as negative or grades one to three based on the positive pixel count ( Fig. 2A) . Most hepatocyte and HCC nuclei were positive, but the percentage of grade 3 nuclei was higher in tumor tissues (normal hepatocytes 33 AE 5%, versus 50 AE 5% of HCC nuclei; P ¼ 0.001) and increased stepwise with the histological grade (Fig. 2B) . The HCC DNA-PKcs level, or percentage of grade 3 nuclei, was not associated with overall survival (data not shown). In a subset analysis of patients receiving palliative doxorubicin in the form of TACE as their first-line Increased PRKDC in HCC and amplification at the DNA locus. PRKDC (A) and ATM (B) mRNA expression levels were analyzed in 132 human liver tissues using Affymetrix U133 Plus 2.0 arrays and expressed as fold change relative to normal liver. Tissues included normal liver (n ¼ 10), cirrhotic liver (n ¼ 13), low-grade dysplastic nodules (LGDN; n ¼ 10), high-grade dysplastic nodules (HGDN; n ¼ 8), and HCV-related HCC (n ¼ 91). PRKDC was significantly elevated in HCC; P ¼ 0.0007. Tumor PRKDC locus copy number was determined using the Affymetrix 500 K Human Mapping Array (C). The maximum value of paired cirrhotic samples was used as a cutoff (mean DNA copy number in 0.5 Mb around PRKDC gene locus, cutoff 2.25). D, relationship between PRKDC locus copy number and mRNA levels (Spearman rank correlation r ¼ 0.6; P ¼ 10
À7
). (20) , combining HCC features, liver function, and patient performance, rather than any single factor, was predictive of survival in this treated group ( Fig. 2D and E ). There were no differences in ATM levels between HCC and paired nontumor liver tissues.
Elevated HCC DNA-PKcs activity was independently associated with poor survival DNA-PK activity, assessed by IHC detection of pDNA-PKcs s2056 , was less prevalent and did not correlate significantly with levels of the native protein (data not shown). However, pDNA-PKcs s2056 was elevated in tumor versus nontumor liver (71 AE 7% positive nuclei vs. 29 AE 12%, respectively, P ¼ 0.003) and increased with histological tumor grade (P ¼ 0.011; Fig. 3A ). The median survival of patients with low tumor pDNA-PKcs s2056 (<25% 3þ nuclei; n ¼ 26) was 35 months compared with 9.9 months in those with >25% 3þ nuclei (n ¼ 19; P ¼ 0.007, Kaplan-Meier; Fig. 3B ). HCC pDNA-PKcs s2056 was independently associated with survival (P ¼ 0.006; HR, 2.91; 95% CI, 1.37-6.17; Supplementary Table S2) . ATM activity (autophosphorylation at serine1981; ref. 21 ) was unchanged in HCC compared with nontumor liver and was not associated with tumor grade or survival. Increased DNA-PKcs protein levels in HCC and a shorter time to progression in patients receiving palliative TACE. DNA-PKcs protein levels were determined immunohistochemically in 45 paired normal and HCC paraffinembedded tissues from cases described in Table 1 . Hepatocyte nuclei were detected using an Aperio Imagescope nuclear algorithm. Level of nuclear expression was determined by pixel intensity, scored as unelevated (0, blue), low (1, yellow), moderate (2, orange), or high (3, red). Application of the algorithm is shown in two paired normal and HCC tissues (A). DNA-PK was detected in the majority of hepatocyte nuclei, and the percentage of total positive nuclei (score 1 B) . Time to radiological progression (TTP) in patients receiving first-line treatment with doxorubicin TACE (patients without extra-hepatic disease, no portal vein thrombosis, Child-Pugh grade A, unsuitable for first-line radiofrequency ablation) is shown in C, where "high DNA-PKcs" cases were those with >48% HCC nuclei grade 3þ (n ¼ 14; range, 48%-99%), compared with "low DNA-PKcs" cases, with <48% grade 3þ (n ¼ 12; range, 0%-43%). Median time to radiological progression was 4.5 versus 16.9 months (P ¼ 0.011, Kaplan-Meier). Survival within this selected group was not significantly associated with any individual factor, including nuclear DNA-PK level (D), but was predicted by BCLC stages A-C, combining tumor, liver function, and performance status (P ¼ 0.017, Kaplan-Meier; E).
DNA-PK expression and activity in a panel of HCC cell lines
Measurement of DDR gene mRNA levels in a panel of 6 HCC cell lines revealed high PRKDC, XRCC6 (Ku70), and XRCC5 (Ku80), with Hep3B and PLC/PRF/5 having the highest and lowest expression, respectively (Fig. 4A) . Other genes involved in NHEJ (XRCC4, LIG4, and XRCC6BP1; Supplementary Fig. S2A ) and ATM (Fig. 4A) were not as highly expressed. The expression of genes involved in HRR was modest, and there was no indication that nucleotide excision repair, base excision repair, or mis-match repair gene expression was altered across the panel (Supplementary Fig. S2B-S2D ). Western blot analysis of DNA-PKcs, Ku70, Ku80 ( Fig. 4B and C) , XRCC4, Ligase 4, and ATM ( Supplementary  Fig. S3 ) revealed abundant DNA-PKcs in all cell lines. DNAP-PK function is critical to the DDR and cell survival and treatment with ; Fig. 4B and C). Irradiation did not affect the levels of Ku70, Ku80, XRCC4, or Ligase 4. To establish a relationship between DNA-PK expression and NHEJ activity, the level of DNA-PKcs was suppressed (shRNA), causing a corresponding reduction in NHEJ repair, assessed using the traffic light reporter system (18) , in HuH7 cells ( Supplementary Fig. S4 and Supplementary Methods).
Effect of DNA-PK and ATM inhibitors on the repair of DNA DSBs
The effect of DNA-PK and ATM inhibitors, NU7441 and KU55933, on DSB repair was investigated in the cell lines that showed a substantial IR induction of ATM and/or DNA-PK activity. DNA DSB induction and repair by HRR were visualized by gH2AX and RAD51 foci, respectively (Fig. 5) . The IR-induced rapid and substantial (5-to 10-fold) increase, then gradual decline, in gH2AX foci was followed by an increase in RAD51 foci, peaking at 24 hours, thereafter gradually declining. NU7441 slightly delayed the time to reach peak gH2AX and hindered resolution of the foci. This was particularly notable in PLC/PRF/5 cells where the foci were still 5x baseline at 24 hours (Fig. 5A) . Interestingly, inhibition of NHEJ by NU7441 caused a very substantial increase in RAD51 foci (Fig. 5A, C , and E), a marker of HRR, for which ATM is presumed to be key. Contrary to expectation, the ATM inhibitor KU55933 did not suppress RAD51 foci (Fig. 5B, D, and F) . Doxorubicin sensitivity, radiosensitivity, and the effect of NU7441 and KU55933
Measurement of the survival of HCC cells exposed to IR and doxorubicin ( Supplementary Fig. S5 ) revealed that HepG2 cells, with high levels of DNA-PK and ATM, were highly radio-and chemoresistant. SNU-182 cells were the most chemosensitive, consistent with their low DNA-PK and ATM activity. SNU-182 cells grew slowly, and the more modest induction of DNA-PK autophosphorylation after irradiation may reflect different temporal kinetics of its activation. Otherwise, ATM and DNA-PK expression and activity were not critical determinants of sensitivity to IR or doxorubicin. NU7441 significantly potentiated IRinduced cytotoxicity by 3-to 40-fold and doxorubicin cytotoxicity by 2-to 50-fold ( Fig. 6A-D; Supplementary Fig. S6 ). Inhibition of ATM by KU55933 caused an up to 44-fold radiosensitization and 10-fold chemosensitization (Supplementary Fig. S7) .
Although NU7441 or KU55933 alone had only a marginal effect on survival, the two together profoundly inhibited survival, particularly in HepG2 and Huh7 cells ( Fig. 6E ; Supplementary Fig. S8 ). The combination of these inhibitors also contributed additional chemo-and radiopotentiation compared with either alone (Supplementary Fig. S9 ). The rank order of sensitivity to doxorubicin compared with IR in the cell lines was markedly different, as was sensitization by NU7441 and KU55933. This was not due to effects on doxorubicin efflux as nuclear accumulation was similar in all cells and was not increased by either NU7441 or KU55933. In contrast, verapamil, an established MDR inhibitor, increased the nuclear accumulation of doxorubicin in all cell lines ( Supplementary  Fig. S10 ).
In vivo studies
Huh7 cells, which reliably formed subcutaneous xenografts and had high DNA-PK levels and activity, were used to explore chemosensitization by NU7441 in vivo. The poor solubility of KU55933 precluded in vivo evaluation of ATM inhibition. Neither doxorubicin nor NU7441, alone or in combination, caused any significant weight loss in the mice ( Supplementary  Fig. S11A ). Scheduled killing based on tumor burden was 7 days after treatment allocation in the control group versus 12 in the NU7441 þ doxorubicin group (Kaplan-Meier, P ¼ 0.043; Supplementary Fig. S11B ). In mice treated with NU7441 þ doxorubicin, the increasing tumor volume trend was modestly reduced compared with control over the study period (Fig. 6F ).
Discussion
Here, we show increased PRKDC mRNA expression in HCC in association with amplification of the PRKDC locus, supporting copy-number gain as a potential mechanism. Having demonstrated tumor-specific overexpression of DNA-PKcs, the protein encoded by PRKDC, in association with MPLA-defined PRKDC locus amplification in resected HCC cases, we demonstrated increased HCC DNA-PKcs in a second cohort of patients undergoing pretreatment diagnostic biopsies. Importantly, increased DNA-PKcs expression was associated with a shorter time to progression in patients receiving cytotoxic TACE therapy. These data support a role for DNA-PK in resistance of HCC to cytotoxic therapy. In all patients in the second cohort, DNA-PK activation (pDNA-PKcs s2056 ) in the diagnostic pretreatment biopsy was independently associated with poorer patient survival. This suggests that activation of DNA-PKcs following gene amplification contributes to tumor progression. Although higher levels of genomic stress associated with inflammation and reactive oxygen species are well recognized in patients with chronic liver disease, and may predispose to carcinogenesis, recent evidence confirms even higher levels of oxidative DNA damage (22, 23) in HCC tissues. Thus, endogenous activation of DNA-PK may reflect high levels of oxidative stress-induced tumor DNA damage in a subgroup of patients with a particularly poor prognosis. DNA-PK stabilization of c-Myc (11), and promotion of genomic instability through competition with high-fidelity HRR (24) , are candidate contributory mechanisms. Taken together, these data identify DNA-PK amplification and elevated expression, in the presence of either endogenous or exogenous activation, as a candidate driver of hepatocarcinogenesis or therapy resistance, respectively.
Similarly, HCC cell lines also had high levels of PRKDC mRNA and DNA-PKcs, with lower expression of other NHEJ genes and ATM, supporting a specific role for DNA-PK, rather than a general one for DDR genes, in hepatocarcinogenesis. Variation in the protein levels between the cell lines unrelated to the mRNA expression was in keeping with translation and protein stability Figure 6 . NU7441 potentiates chemotherapy and radiation-induced cytotoxicity and delays xenograft tumor growth. HCC cells were exposed to IR 1 or 2 Gy (A, B) or doxorubicin 10 or 100 nmol/L (C, D) and incubated for 24 hours before reseeding in drug-free medium and incubation for 14 to 21 days for colony formation. Colony forming assays with (white bars) or without (black bars) 1 mmol/L NU7441 for 1 hour before IR exposure and for 24 hours after, or DMSO (black bars) versus 1 mmol/L NU7441 (black bars) for 1 hour before doxorubicin and for 24 hours after demonstrate NU7441 potentiation, with reduced cell survival. In the absence of IR or doxorubicin, the combination of NU7441 (1 mmol/L) and KU55933 (10 mmol/L) inhibits cell survival (E). Data are plotted as mean AE SEM for a minimum of 3 independent experiments, Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001; ÃÃÃÃ , P < 0.0001. Mice with measurable Huh7 xenografts were treated (i.p.) with saline (control, n ¼ 9), 10 mg/kg NU7441 (n ¼ 9), 2 mg/kg doxorubicin (n ¼ 9), or both 10 mg/kg NU7441 and 2 mg/kg doxorubicin (n ¼ 9) daily for five days (F). Increasing tumor volume was delayed in treatment groups compared with control animals, with the trend in the combination treatment group in keeping with modest potentiation.
being dysregulated in cancer (25) . Neither DNA-PK nor ATM expression/activity predicted the rate of DSB repair or chemo-or radiosensitivity in the HCC cell lines, reflecting the complexity and multifactorial nature of the DDR. Nevertheless, suppression of DNA-PKcs levels in HuH7 cells reduced repair of I-SceIinduced DSBs by NHEJ. Furthermore, inhibition of DNA-PK activity retarded the resolution of DSBs, sensitizing HCC cells to the effects of doxorubicin and IR.
Both DNA-PK suppression and inhibition conferred a shift toward HRR, consistent with the hypothesis that NHEJ and HRR compete for DNA breaks (26) . In contrast with previous reports in other cells (27, 28) , KU55933 did not suppress IRinduced RAD51 focus formation, suggesting that ATM kinase activity is not essential for HRR in HCC. Our subsequent demonstration that the combination of NU7441 and KU55933 had a substantial impact on HCC cell survival in the absence of a DNA-damaging agent is indicative of synthetic lethality, as neither alone was significantly cytotoxic. These observations support recent studies indicating that ATM deficiency confers sensitivity to DNA-PK inhibition (29) . Furthermore, the ability of NU7441 and KU55933 to chemo-and/or radiosensitize in all the cell lines was encouraging for their potential as anticancer therapeutics. Although extending these studies to the in vivo setting was hampered by the rapid growth of the tumor xenografts, the combination of NU7441 with doxorubicin did suppress the rate of xenograft growth.
These data are novel and suggest that (i) the combination of inhibitors of DNA repair pathway inhibitors may induce HCC cell death and (ii) the potentiation of tumor damage by cytotoxic agents may facilitate their use at doses much less toxic to nontumor liver, warranting further exploration. Of more immediate clinical relevance is the evidence that HCC DNA-PKcs expression by IHC in pretreatment diagnostic biopsy material predicts responsiveness to TACE. TACE treatment has been controversial, although in fit (BCLC B) patients, there is overall survival benefit (3). Here, we report a biomarker that may identify patients with more aggressive tumors, potentially with a lesser response to TACE. Because confirmatory HCC biopsy is not routinely performed, our present observational study is hampered by a small cohort size of radiologically atypical patients, as well as heterogeneity in terms of HCC stage. However, in line with the management of other nonresectable cancers, where tissue-based molecular testing guides decision making (30), we suggest that the time is approaching where biopsy characterization of HCC will be needed for better patient stratification.
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